K
Kelly Kersten
Researcher at University of California, San Francisco
Publications - 26
Citations - 5538
Kelly Kersten is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Immune system & Cancer. The author has an hindex of 12, co-authored 19 publications receiving 3093 citations. Previous affiliations of Kelly Kersten include University of California, Berkeley & Netherlands Cancer Institute.
Papers
More filters
Journal ArticleDOI
Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies,Edward W. Roberts,Kelly Kersten,Vincent Chan,Douglas F. Fearon,Miriam Merad,Lisa M. Coussens,Dmitry I. Gabrilovich,Suzanne Ostrand-Rosenberg,Suzanne Ostrand-Rosenberg,Catherine C. Hedrick,Robert H. Vonderheide,Mikael J. Pittet,Rakesh K. Jain,Weiping Zou,T. Kevin Howcroft,Elisa C. Woodhouse,Robert A. Weinberg,Matthew F. Krummel +18 more
TL;DR: By parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient’s tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.
Journal ArticleDOI
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.
Seth B. Coffelt,Kelly Kersten,Chris W. Doornebal,Jorieke Weiden,Kim Vrijland,Cheei-Sing Hau,Niels J. M. Verstegen,Metamia Ciampricotti,Lukas J. A. C. Hawinkels,Jos Jonkers,Karin E. de Visser +10 more
TL;DR: It is shown that tumours maximize their chance of metastasizing by evoking a systemic inflammatory cascade in mouse models of spontaneous breast cancer metastasis, and targeting this novel cancer-cell-initiated domino effect within the immune system—the γδ T cell/IL-17/neutrophil axis—represents a new strategy to inhibit metastatic disease.
Journal ArticleDOI
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T cell Immunity
Mikhail Binnewies,Adriana M. Mujal,Joshua L. Pollack,Alexis J. Combes,Emily A. Hardison,Kevin C. Barry,Jessica Tsui,Megan K. Ruhland,Kelly Kersten,Marwan Abushawish,Marko Spasic,Jonathan P. Giurintano,Vincent Chan,Adil Daud,Patrick K. Ha,Chun Jimmie Ye,Edward W. Roberts,Matthew F. Krummel +17 more
TL;DR: This work comprehensively characterized myeloid cells in tumor draining lymph nodes of mice and identified two subsets of conventional type-2 dendritic cells (cDC2) that traffic from tumor to tdLN and present tumor-derived antigens to CD4+ Tconv, but then fail to support antitumor CD4-Tconv differentiation.
Journal ArticleDOI
Genetically engineered mouse models in oncology research and cancer medicine.
TL;DR: GEMMs have been used to validate candidate cancer genes and drug targets, assess therapy efficacy, dissect the impact of the tumor microenvironment, and evaluate mechanisms of drug resistance.
Journal ArticleDOI
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.
Camilla Salvagno,Metamia Ciampricotti,Metamia Ciampricotti,Sander Tuit,Sander Tuit,Cheei-Sing Hau,Antoinette van Weverwijk,Seth B. Coffelt,Seth B. Coffelt,Kelly Kersten,Kim Vrijland,Kevin Kos,Thomas Ulas,Ji-Ying Song,Chia Huey Ooi,Dominik Rüttinger,Philippe A. Cassier,Jos Jonkers,Joachim L. Schultze,Joachim L. Schultze,Carola Ries,Karin E. de Visser +21 more
TL;DR: In this paper, the authors show that targeting tumour-associated macrophages by colony-stimulating factor-1 receptor (CSF-1R) blockade in the K14cre;Cdh1F/F;Trp53F/f transgenic mouse model for breast cancer stimulates intratumoural type I interferon (IFN) signalling, which enhances the anticancer efficacy of platinum-based chemotherapeutics.